Association of polymorphisms in tumor necrosis factor alpha and beta genes with increased risk for oral cancer

Anticancer Research

Volumn 29, Issue 6, 2009, Pages 2379-2386

  Yapijakis, Christos ^a   Serefoglou, Zoe ^a   Vylliotis, Antonis ^a   Nkenke, Emeka ^b,c   Derka, Spyridoula ^a   Vassiliou, Stavros ^a   Avgoustidis, Dimitrios ^a   Neukam, Friedrich Wilhelm ^b,c   Patsouris, Efstratios ^a   Vairaktaris, Eleftherios ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^c University of Erlangen ^*  (Germany)

Author keywords

Genetic association study; Oncogenesis; Oral cancer; Polymorphism; Tumor necrosis factor alpha; Tumor necrosis factor beta

Indexed keywords

DNA;

ADULT; AGE DISTRIBUTION; AGED; ALCOHOL CONSUMPTION; ALLELE; ARTICLE; CANCER PATIENT; CANCER RISK; CANCER STAGING; CONTROLLED STUDY; ETHNICITY; FAMILY HISTORY; FEMALE; GENDER; GENE; GENE EXPRESSION; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MOUTH CANCER; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SMOKING; SQUAMOUS CELL CARCINOMA; THROMBOSIS; TUMOR NECROSIS FACTOR ALPHA GENE; TUMOR NECROSIS FACTOR BETA GENE;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; FEMALE; GENOTYPE; HUMANS; LYMPHOTOXIN-ALPHA; MALE; MIDDLE AGED; MOUTH NEOPLASMS; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; RISK FACTORS; SMOKING; TUMOR NECROSIS FACTOR-ALPHA;

EID: 67650921930     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Williams HK: Molecular pathogenesis of oral carcinoma. J Clin Pathol 53: 165-172, 2000.
2. Vairaktaris E, Yapijakis C, Vylliotis A, Kessler P, Vylliotis A, Ries J, Wiltfang J, Vassiliou S, Derka S and Neukam FW: Methylenetetrahydrofolate reductase polymorphism and minor increase of risk for oral cancer. J Cancer Res Clin Oncol 132: 219-222, 2006.
3. Aggarwal BB, Shishodia S, Sandur SK, Pandey MK and Sethi G: Inflammation and cancer: how hot is the link? Biochem Pharmacol 72: 1605-1621, 2006.
4. Bazzoni F and Beutler B: The tumor necrosis factor ligand and receptor families. N Engl J Med 334: 1717-1725, 1996. (Pubitemid 26193625)
5. Wilson AG, di Giovine FS and Duff GW: Genetics of tumour necrosis factor-alpha in autoimmune, infectious, and neoplastic diseases. J Inflamm 45: 1-12, 1995.
6. Wilson AG, Symons JA, McDowell TL, McDevitt HO and Duff GW: Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. Proc Natl Acad Sci USA 94: 3195-3199, 1997.
7. Conway DJ, Holland MJ, Bailey RL, Campbell AE, Mahdi OSM, Jennings R, Mbena E and Mabey DCW: Scarring trachoma is associated with polymorphism in the tumor mecrosis factor alpha (TNF-α) gene promoter and with elevated TNF-α levels in tear fluid. Infect Immun 65: 1003-1006, 1997.
8. Keatings VM, Cave SJ, Henry MJ, Morgan K, O'Connor CM, FitzGerald MX and Kalsheker N: A polymorphism in the tumor necrosis factor-α gene promoter region may predispose to a poor prognosis in COPD. Chest 118: 971-975, 2000.
9. Cuenca J, Pérez CA, Aguirre AJ, Schiattino I and Aguillón JC: Genetic polymorphism at position -308 in the promoter region of the tumour necrosis factor (TNF): Implications of its allelic distribution on susceptibility or resistance to diseases in the Chilean population. Biol Res 34: 3-8, 2001.
10. Guo W, Wang N, Li Y and Zhang JH: Polymorphisms in tumor necrosis factor genes and susceptibility to esophageal squamous cell carcinoma and gastric cardiac adenocarcinoma in a population of high incidence region of North China. Chin Med J 118: 1870-1878, 2005. (Pubitemid 41748746)
11. Azmy IA, Balasubramanian SP, Wilson AG, Stephenson TJ, Cox A, Brown NJ and Reed MW: Role of tumor necrosis factor gene polymorphism (-308 and -238) in breast cancer susceptibility and severity. Breast Cancer Res 6: 395-400, 2004.
12. Saito S, Kasai Y, Nomoto S, Fujiwara M, Akiyama S, Ito K and Nakao A: Polymorphism of tumor necrosis factor in esophageal, gastric or colorectal carcinoma. Hepatogastroenterol 48: 468-470, 2001.
13. Jablonska E, Piotrowski L and Grabowska Z: Serum Levels of IL-1b, IL-6, TNF-a, sTNF-RI and CRP in patients with oral cavity cancer. Pathol Oncol Res 3: 126-129, 1997.
14. Chen WC, Tsai MH, Wan L, Chen WC, Tsai CH and Tsai FJ: CYP17 and tumour necrosis factor-alpha gene polymorphisms are associated with risk of oral cancer in Chinese patients in Taiwan. Acta Otolaryngol 125: 96-99, 2005.
15. Messer G, Spengler U, Jung MC, Honold G, Blomer K, Pape GR, Riethmuller G and Weiss EH: Polymorphic structure of the tumor necrosis factor (TNF) locus: an NcoI polymorphism in the first intron of the human TNF-beta gene correlates with a variant amino acid in position 26 and a reduced level of TNF-beta production. J Exp Med 173: 209-219, 1991.
16. Pociot F, Briant L, Jongeneeel CV, Mölvig J, Worsaae H, Abbal M, Thomsen M, Nerup J and Cambon-Thomsen A: Association of tumor necrosis factor (TNF) and class II major histocompatibility complex alleles with the secretion of TNF-α and TNF-β by human mononuclear cells: a possible link to insulin-dependent diabetes mellitus. Eur J Immunol 23: 224-231, 1993. (Pubitemid 23031920)
17. Trabace S, Brioli G, Lulli P, Morellini M, Giacovazzo M, Cicciarelli G and Martelletti P: Tumor necrosis factor gene polymorphism in migraine. Headache 42: 341-345, 2002.
18. Kamali-Sarvestani E, Gharesi-Fard B, Sarvari J and Talei AR: Association of TNF-α and TNF-β gene polymorphism with steroid receptor expression in breast cancer patients. Pathol Oncol Res 11: 99-102, 2005.
19. Bogunia-Kubik K, Polak M and Lange A: TNF polymorphisms are associated with toxic but not with aGVHD complications in the recipients of allogeneic sibling haematopoietic stem cell transplantation. Bone Marrow Transplant 32: 617-722, 2003. (Pubitemid 37185098)
20. Ho SY, Wang YJ, Chen HL, Chen CH, Chang CJ, Wang PJ, Chen HW and How-Ran G: Increased risk of developing hepatocellular carcinoma associated with carriage of the TNF2 allele of the -308 tumor necrosis factor-alpha promoter gene. Cancer Causes Control 15: 657-663, 2004.
21. Shih CM, Lee YL, Chiou HL, Chen W, Chang G and Chou ML: Association of TNF-alpha polymorphism with susceptibility to and severity of non-small cell lung cancer. Lung Cancer 52: 15-20, 2006.
22. Bel Hadj Jrad B, Chatti A, Laatiri A, Ahmed SB, Romdhane A, Ajimi S and Chouchane L: Tumor necrosis factor promoter gene polymorphism associated with increased susceptibility to non-Hodgkin's lymphomas. Eur J Haematol 78: 117-122, 2007.
23. Braun NU, Michel BP, Ernst R, Metzner R, Bitsch A, Weber F and Rieckmann P: Gene polymorphism at position -308 of the tumor necrosis-factor-α (TNF-α) in multiple sclerosis and its influence on the regulation of TNF-α production. Neurosci Lett 215: 75-78, 1996.
24. Uglialoro AM, Turbay D, Pesaavento PA, Delgado JC, McKenzie FE, Gribben JG, Hartl D, Yunis EJ and Goldfeld AE: Identification of three new single nucleotide polymorphisms in the human tumor necrosis factor-α gene promoter. Tissue Antigens 52: 359-367, 1998.
25. Suriano AR, Sanford AN, Kim N, Kennedy S, Henderson MJ, Dietzmann K and Sullivan KE: GCF2/LRRFIP1 represses tumor necrosis factor alpha expression. Mol Cell Biology 25: 9073-9081, 2005. (Pubitemid 41429095)
26. Oyama T, Matsushita K, Sakuta T, Tokuda M, Tatsuyama S, Nagaoka S and Torii M: Roxithromycin inhibits tumor necrosis factor-alpha-induced matrix metalloproteinase-1 expression through regulating mitogen-activated protein kinase phosphorylation and Ets-1 expression. J Periodontal Res 42: 53-61, 2007.
27. Vairaktaris E, Goutzanis L, Kalokerinos G, Yannopoulos A, Yapijakis C, Vassiliou S, Spyridonidou S, Vylliotis A, Nkenke E, Lazaris AC, Tesseromatis C and Patsouris E: Diabetes increases both N-ras and ets-1 expression during rat oral oncogenesis resulting in enhanced cell proliferation and metastatic potential. In Vivo 21: 615-621, 2007. (Pubitemid 47232662)
28. Nonomura N, Tokizane T, Nakayama M, Inoue H, Nishimura K, Muramatsu M and Okuyama A: Possible correlation between polymorphism in the tumor necrosis factor-beta gene and the clinicopathological features of bladder cancer in Japanese patients. Int J Urol 13: 971-976, 2006.
29. Oliveira ID, Petrilli AS, Tavela MH, Zago MA and de Toledo SR: TNF-alpha, TNF-beta, IL-6, IL-10, PECAM-1 and the MPO inflammatory gene polymorphisms in osteosarcoma. J Pediatr Hematol Oncol 29: 293-297, 2007. (Pubitemid 46707507)
30. Lejeune FJ: Clinical use of TNF revisited: improving penetration of anti-cancer agents by increasing vascular permeability. J Clin Invest 110: 433-435, 2002. (Pubitemid 34919695)
31. Balkwill F: Tumor necrosis factor or tumor promoting factor? Cytokine Growth Factor Rev 13: 135-141, 2002.
32. Yoshida S, Ono M, Shono T, Izumi H, Ishibashi T, Suzuki H and Kuwano M: Involvement of interleukin-8, vascular endothelial growth factor, and basic fibroblast growth factor in tumor necrosis factor alpha-dependent angiogenesis. Mol Cell Biol 17: 4015-4023, 1997. (Pubitemid 27281877)
33. Leber TM and Balkwill FR: Regulation of monocyte MMP-9 production by TNF-a and a tumor-derived soluble factor (MMPSF). Br J Cancer 78: 724-732, 1998. (Pubitemid 28418303)
34. Vairaktaris E, Vassiliou S, Nkenke E, Serefoglou Z, Derka S, Tsigris C, Vylliotis A, Yapijakis C, Neukam FW and Patsouris E: A metalloproteinase-9 polymorphism which affects its expression is associated with increased risk for oral squamous cell carcinoma. Eur J Surg Oncol 34: 450-455, 2008.
35. Vairaktaris E, Yapijakis C, Serefoglou Z, Derka S, Vassiliou S, Nkenke E, Vylliotis A, Wiltfang J, Avgoustidis D, Critselis E, Neukam FW and Patsouris E: The interleukin-8 (-251A/T) polymorphism is associated with increased risk for oral squamous cell carcinoma. Eur J Surg Oncol 33: 504-507, 2006.
36. Schindler R, Mancilla J, Endres S, Ghorbani R, Clark SC and Dinare A: Correlations and interactions in the production of interleukin- (IL-6), IL-1, and tumor necrosis factor (TNF) in human blood mononuclear cells: IL-6 suppresses IL-1 and TNF. Blood 75: 40-47, 1990. (Pubitemid 20031487)
37. Vairaktaris E, Yiannopoulos A, Vylliotis A, Yapijakis C, Derka S, Vassiliou S, Nkenke E, Serefoglou Z, Ragos V, Tsigris C, Vorris E, Critselis E, Avgoustidis D, Neukam FW and Patsouris E: Strong association of interleukin-6 -174 G>C promoter polymorphism with increased risk for oral cancer Int J Biol Markers 21: 246-250, 2006.
38. Davies FE, Rollinson SJ, Rawstron AC, Roman E, Richards S, Drayson M, Child JA and Morgan GJ: High-produced haplotypes of tumor necrosis factor alpha and lymphotoxin alpha are associated with an increased risk of myeloma and have an improved progression-free survival after treatment. J Clin Oncol 18: 2843-2851, 2000. (Pubitemid 30620072)
39. Hinsbergh WM, Berg EA, Fiers W and Dooijewaard G: Tumor necrosis factor induces the production of urokinase-type plasminogen activator by human endothelial cells. Blood 75: 1991-1998, 1990.
40. Wilson AG, de Vries N, Pociot F, di Giovine FS, van der Plutte LB and Duff GW: An allelic polymorphism within the human tumor necrosis factor alpha promoter region is strongly associated with HLA A1, B8, and DR3 alleles. J Exp Med 177: 557-560, 1993.
41. Cox A, Gonzales AM, Wilson AG and Wilson RM: Comparative analysis of the genetic associations of HLA-DR3 and tumor necrosis factor alpha wth human IDDM. Diabetologia 37: 500-503, 1994. (Pubitemid 24133653)
42. Takeuchi F, Nakano K, Nabeta H, Hong GH, Kawasugi K, Mori M, Okudaira H, Kuwata S and Tanimoto K: Genetic contribution of the tumor necrosis factor (TNF) β+252*2/2 genotype, but not the TNFα,β microsatellite alleles, to systemic lupus erythematosus in Japanese patients. J Immunogenet 32: 173-178, 2004.